Editorial: Insights in experimental pharmacology and drug discovery: 2022

Alexandra Latini, Latini A, Carmen Peralta Uroz, Uroz CP, Andrés Trostchansky, Trostchansky A
Frontiers in pharmacology · 2023 · vol. 14 , pp. 1250936 · doi:10.3389/fphar.2023.1250936 · PMID:37675048 · PMC10478218
Other OA: gold CC-BY-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-29 ⓘ

This editorial highlights insights from experimental pharmacology and drug discovery in 2022, with authors confirming substantial intellectual contributions and the absence of commercial conflicts.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-29 · read from full text ⓘ

This editorial serves as a brief introduction to the 2022 insights in experimental pharmacology and drug discovery, acknowledging the intellectual contributions of all listed authors. It includes standard declarations regarding the absence of commercial or financial conflicts of interest and clarifies that the views expressed are solely those of the authors rather than their affiliated organizations or the publisher. The text functions primarily as an administrative and ethical statement for the publication rather than presenting original research data or specific scientific findings. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 648 characters · extracted from epmc-fulltextxml · 3 sections · click to expand

Author

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’S

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: epmc-fulltextxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T21:41:14.423456+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Per Europe PMC